Page 1

+ + + + + + + + BIOVICA + + + + + ● + ● + + SEK 000s Net sales Operating profit ( loss ) Profit ( loss ) for the period Earnings per share , after dilution + + + + Significant events during the third quarter + + + + + + Significant events after the end of the period Q3 20/21 Q3 19/20 1,376 55 -11,062 -10,909 -0.38 + -7,433 -7,515 -0.32 + Q3 Interim report 2000 20 November - January 2020/2021 FDA resumes review of DiviTum ⓇTKa submission + + + May - Jan 20/21 1,759 -28,012 -27,491 -0.97 May - Jan 19/20 1,671 -19,520 -19,540 -0.83 + New study in Italy started . The FDA resumed its review of the 510 ( k ) application at the end of January . + + + The results from four studies were presented at San Antonio Breast Cancer Symposium . New study in UK and Sweden started . Full year 19/20 1,671 -29,816 -30,318 -1.29 + + The PROMIX breast cancer study at Karolinska University Hospital has been published in the scientific journal , ESMO Open . Audiocast : When : 18 March 2021 at 10.00 CET Where : https://tv.streamfabriken.com/biovica-international-q3-2020-2021 Phone numbers : SE : +46850558357 , DK : +4578150109 , UK : +443333009034 , US : +18332498404 Broadcast language : in English + + + +